Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges (2019 - 2025)

Tg Therapeutics has reported Amortization of Deferred Charges over the past 7 years, most recently at $288000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $288000.0 for Q4 2025, down 4.95% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (down 78.5% YoY), and the annual figure for FY2025 was $1.2 million, down 39.85%.
  • Amortization of Deferred Charges for Q4 2025 was $288000.0 at Tg Therapeutics, down from $304000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for TGTX hit a ceiling of $4.0 million in Q3 2024 and a floor of $200000.0 in Q2 2021.
  • Median Amortization of Deferred Charges over the past 5 years was $461000.0 (2022), compared with a mean of $607950.0.
  • Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 566.67% in 2024 and later tumbled 92.4% in 2025.
  • Tg Therapeutics' Amortization of Deferred Charges stood at $386000.0 in 2021, then grew by 19.43% to $461000.0 in 2022, then soared by 38.61% to $639000.0 in 2023, then crashed by 52.58% to $303000.0 in 2024, then decreased by 4.95% to $288000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $288000.0 (Q4 2025), $304000.0 (Q3 2025), and $304000.0 (Q2 2025) per Business Quant data.